Clinical Trial

HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Study acronym: HEM-iSMART E
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL. Sub-protocol E is a phase I/II trial evaluating the safety and efficacy of capivasertib + venetocolax in combination with dexamethasone in children and AYA with R/R ped ALL/LBL whose tumor present with alterations of the PAM pathway, or lacking any mutations.
Trial Details
NCT Number NCT07175415
Lead Sponsor Princess Maxima Center for Pediatric Oncology
Collaborators: AstraZeneca, AbbVie
Conditions Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
Enrollment 42 participants
Start Date 2026-10-01
Primary Completion 2031-10-01 (estimated)
Study Completion 2032-10-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-16